Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX101 pharmacokinetic, safety, and preliminary efficacy study in unilateral total knee arthroplasty
jRCT2051240201Phase 2Completed
- Sponsor
- Maruishi Pharmaceutical Co., Ltd.
- Start
- Jan 2025
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATX101 in postoperative pain, sponsored by Maruishi Pharmaceutical Co., Ltd. Primary endpoints: Plasma ATX101 concentrations, Pharmacokinetic parameters and 4 more. Started Jan 2025; status: completed.
02
Drugs
ATX101
03
Conditions
postoperative pain
Beyond the preview
Go deeper on jRCT2051240201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240201.